<乌鸦传媒>Combination Shows Promise in Post-Osimertinib Lung Cancer Responses in 36% with amivantamab-lazertinib, 47% with EGFR/MET resistance Jun 06, 2021
<乌鸦传媒>Antibody-Drug Conjugate Active in Resistant Lung Cancer Responses in 39% of EGFR inhibitor-resistant patients with patritumab deruxtecan Jun 05, 2021
<乌鸦传媒>Chemoimmunotherapy Tied to Better Outcomes in Advanced NSCLC PD-L1 status and age play key roles in success of combined regimen versus immunotherapy alone Jun 05, 2021
<乌鸦传媒>Lymph Node Findings on PET: Cancer or COVID Vaccine? Post-jab radiotracer uptake "could prompt unnecessary biopsies and treatments" May 26, 2021
<乌鸦传媒>Anti-PD-L1 Plus SBRT Enhances Major Responses in Early NSCLC Neoadjuvant combo needs to be validated in a larger randomized trial May 20, 2021
<乌鸦传媒>PD-L1 Inhibitor Thwarts Recurrence in Early Lung Cancer Risk of death, recurrence 34% lower with atezolizumab after surgery and chemo May 19, 2021
<乌鸦传媒>Op-Ed: Is FDA's Cigarette Ban Just Smoke and Menthols? Actually implementing a ban on menthol cigarettes and cigars could take years May 03, 2021
<乌鸦传媒>SBRT Safe for Cancer Patients With Multiple Metastases Late adverse events in phase I trial indicate need for extended follow-up May 03, 2021
<乌鸦传媒>Lung Cancer Survival Continues to Rise With Immunotherapy Twice as many patients with advanced NSCLC alive at 5 years with pembrolizumab vs chemo Apr 29, 2021
<乌鸦传媒>New Anti-PD1 Drugs Boost Survival in Treated Lung Cancer Questions about generalizability of results with China-developed therapies Apr 14, 2021
<乌鸦传媒>A Win for Nivolumab as Preoperative Therapy for Lung Cancer Pathologic CR rate 12 times higher with the addition of anti-PD-1 agent to chemo Apr 11, 2021
<乌鸦传媒>USPSTF Expands Lung Cancer Screening Criteria Lower age for starting, new definition of 'heavy smoker' double eligibility for screening Mar 09, 2021
<乌鸦传媒>Entrectinib Impresses in Certain Lung Cancers Durable responses in most patients with advanced NSCLC, active in brain mets Mar 05, 2021
<乌鸦传媒>New Targeted Therapies Show Promise in Cancer Selected abstracts from the ESMO Targeted Anticancer Therapies virtual meeting Mar 03, 2021
<乌鸦传媒>Neoadjuvant Dual ICI Leads to Clinical Benefit in Operable NSCLC More than one-third of patients achieved major pathologic response with nivolumab-ipilimumab. Feb 18, 2021
<乌鸦传媒>New Drug OK'd for Chemo-Induced Myelosuppression in SCLC CDK4/6 inhibitor cut the risk for severe neutropenia in small-cell lung cancer patients Feb 13, 2021
<乌鸦传媒>Dustin Diamond's Small Cell Lung Cancer "Saved by the Bell" actor diagnosed after exhaustive testing Feb 02, 2021
<乌鸦传媒>KRAS Inhibitor Continues to Impress in NSCLC Sotorasib yielded deep and durable responses in over one-third of patients Feb 01, 2021
<乌鸦传媒>Nab-Paclitaxel as Possible Option for Relapsed NSCLC Noninferior to docetaxel for OS, though impact on clinical practice questioned Feb 01, 2021
<乌鸦传媒>Should COVID-Strained Centers Hit Pause on Lung Cancer Screening? A debate on what stopping scans would do to health systems, patients Feb 01, 2021
<乌鸦传媒>Promising Data for Preop Checkpoint Inhibition in NSCLC Major response rate of 21%, encouraging survival with single-agent atezolizumab Jan 31, 2021
<乌鸦传媒>First-Ever Survival Bump in Relapsed Mesothelioma OS, PFS improved with nivolumab, but questions remain about alternatives, biomarkers Jan 30, 2021
<乌鸦传媒>Dual Checkpoint Blockade No Help in PD-L1-High NSCLC Single-agent pembrolizumab wins out as first-line therapy for advanced disease Jan 30, 2021
<乌鸦传媒>COVID Affects Cancer Care, Patients' Mental Health Studies: fewer diagnoses, more severe disease, worse outcomes, distressed patients Jan 29, 2021
<乌鸦传媒>Montana Oncologist Fired for Misdiagnosing, Overtreating Patients But some rally around him Jan 26, 2021
<乌鸦传媒>Cancer and COVID; Booze and Cancer; 'Screech' Starts Chemo News, features, and commentary about cancer-related issues Jan 21, 2021
<乌鸦传媒>Targeted Combo Fails in EGFR-Mutant NSCLC Osimertinib-bevacizumab no better than osimertinib alone Jan 07, 2021
<乌鸦传媒>Baby Boys Get Cancer From Mom During Birth Report highlights potential fetal implications of undiagnosed maternal cervical cancer Jan 06, 2021
<乌鸦传媒>Lorlatinib Shows 'Striking' CNS Activity in ALK Lung Cancer But unusual adverse events may hold therapy back Nov 18, 2020
<乌鸦传媒>CDK4/6 Inhibitor in SCLC Cuts Chemo-Induced Myelosuppression Reduced severe neutropenia and less need for supportive care with trilaciclib Oct 20, 2020
<乌鸦传媒>Dual Checkpoint Blockade With Some Chemo Boosts OS in NSCLC Nivolumab-ipilimumab with two cycles of chemotherapy improved survival, regardless of histology or PD-L1 status Oct 17, 2020
<乌鸦传媒>Drug Active in 'Undruggable' KRAS-Mutant NSCLC Responses in a third of patients, disease control rate approaching 90% Sep 20, 2020
<乌鸦传媒>A Closer Look at FDA Decision to Pull Lorcaserin More cancers, multiple primaries, and deaths in CAMELLIA-TIMI 61 influenced agency decision Sep 09, 2020
<乌鸦传媒>Even 'Light' Smoking Ups Lung Cancer Risk Mortality approaches that of heavy smokers Sep 09, 2020
<乌鸦传媒>In Lupus, Older Age and Male Sex Raise Cancer Risk Role of most medications, though, not yet clear Aug 21, 2020
<乌鸦传媒>Chemo-Free Regimen Boosts OS in Mesothelioma Big advantage for nivolumab-ipilimumab in nonepithelioid tumors drives advantage over chemo Aug 09, 2020
<乌鸦传媒>Another ALK Drug Tops Crizotinib in First-Line NSCLC Ensartinib doubled PFS over older standard, with improved CNS activity Aug 08, 2020
<乌鸦传媒>COVID-19 More Deadly Than Cancer Itself? Highlights from the AACR conference on COVID-19 and cancer Jul 24, 2020
<乌鸦传媒>The Serious Conversation: Delivering Bad News by Telemedicine As office visits move online, clinicians discuss breaking life-changing diagnoses virtually Jul 13, 2020
<乌鸦传媒>Cancer Immunotherapy Tied to Severe COVID-19 Outcomes Nearly threefold increased risk of hospitalization, severe respiratory illness Jun 25, 2020
